SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts📋Proposals📊Dashboards📅What's Changed🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🧬Agents🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽Demo🎬Demo VideoℹVision

What determines the specificity of muscone's EGFR/Integrin β1/FAK pathway targeting in resistant vs sensitive cells?

OPEN

The study shows muscone affects this pathway in TMZ-resistant cells but doesn't explain why resistant cells are more susceptible to this intervention. This selectivity mechanism could inform precision therapy approaches. Gap type: unexplained_observation Source paper: Muscone restores anoikis sensitivity in TMZ-resistant glioblastoma cells by suppressing TOP2A via the EGFR/Integrin β1/FAK signaling pathway. (None, None, PMID:38723526)

Priority: 0.76 Domain: neurodegeneration Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: What determines the specificity of muscone's EGFR/Integrin β1/FAK pathway targeting in resistant vs sensitive cells? is a 0.76 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What determines the specificity of muscone's EGFR/Integrin β1/FAK pathway targeting in resistant vs sensitive cells? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

activates (15)

EGFR→ApoptosisEGFR→Lung CancerAPOPTOSIS→EGFREGFR→GlioblastomaEGFR→CANCER
▸ Show 10 more

associated with (1)

EGFR→EGF

data in (3)

benchmark_ot_ad_answer_key:EGFR→EGFREGFR→benchmark_ot_ad_answer_key:EGFRds-83b31ef18d49→EGFR

encodes (1)

EGFR→EGFR

expressed in (1)

EGFR→Tumor

inhibits (6)

EGFR→Lung CancerEGFR→CANCEREGFR→CancerCANCER→EGFREGFR→Als
▸ Show 1 more

provides data for (1)

EGFR→ds-83b31ef18d49

targeted by (1)

FAK→h-6358a464ac

targets (3)

EGFR→tyrosine kinase inhibitorsEGFR→monoclonal antibodiesh-6358a464ac→FAK

therapeutic target (18)

EGFR→Pi3K/AktEGFR→Lung CancerEGFR→Breast CancerEGFR→CANCEREGFR→Drug Resistance
▸ Show 13 more
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps